Infigratinib

Infigratinib is an orally administered, small molecule inhibitor that targets fibroblast growth factor receptor (FGFR) proteins. It is specifically designed to inhibit FGFR1, FGFR2, and FGFR3, which are receptor tyrosine kinases involved in cell growth, proliferation, and survival. Aberrant activation of FGFR signaling, often due to genetic alterations like amplifications, translocations, or mutations, is implicated in the development and progression of various cancers.

Infigratinib has been investigated for its therapeutic potential in several types of solid tumors, particularly those driven by FGFR alterations. Clinical trials have focused on its efficacy in cholangiocarcinoma, a cancer of the bile ducts, as well as other FGFR-altered malignancies such as urothelial carcinoma and certain types of lung cancer. The drug works by blocking the downstream signaling pathways activated by these altered FGFRs, thereby inhibiting tumor cell growth and survival.

The development of infigratinib is part of a broader effort to develop targeted therapies for cancers with specific genetic drivers. Its effectiveness is often dependent on the presence of specific FGFR alterations in a patient's tumor, making genetic testing a crucial step in determining eligibility for treatment. As with many targeted therapies, potential side effects are monitored during treatment, and management strategies are in place to address them. Research continues to explore its use in different cancer types and in combination with other therapeutic agents.